Relapsed Adult AML Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Relapsed Adult AML clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

Relapsed Adult AML
University Hospital, Lille5 enrolled1 locationNCT06649227
Recruiting
Phase 1

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Refractory AMLRelapsed Adult AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24 enrolled1 locationNCT06307054
Recruiting
Phase 2

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, AcuteRefractory LeukemiaRelapsed Adult AML
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT05305859
Recruiting
Phase 1Phase 2

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more
Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574
Recruiting
Not Applicable

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Relapsed Adult AMLHigh-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid Leukemia
Massachusetts General Hospital2,300 enrolled20 locationsNCT05237258
Recruiting
Phase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation33 enrolled20 locationsNCT06022003
Recruiting
Phase 1

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Relapsed Adult AML
Pacylex Pharmaceuticals35 enrolled1 locationNCT06613217